Eran Elinav

Elinav was awarded the Rappaport prize for biomedical research in 2015, the Levinson award for basic science research in 2016, the Landau prize of Immunology in 2018 and was inducted to the American Academy of Microbiology in 2021.

In 2012 Elinav moved to the Weizmann Institute of Science and in 2016 was made a professor. He heads the Institute of Microbiome research and the Center of Host-Pathogen Interaction Research at the Weizmann Institute of Science and the Microbiome & Cancer Division at the DKFZ.

In 2009 Elinav earned a Ph.D. in immunology from the Weizmann Institute of Science, advised by Zelig Eshhar, after developing the Chimeric Antigen Receptor Regulatory T cell (CAR-Treg) approach, as treatment of inflammatory bowel disease and autoimmunity. In 2009-2012 he followed by a post-doc at Yale University, advised by Richard Anthony Flavell, in which he discovered the NLRP6 inflammasome.

He served as a senior physician-scientist at the Tel Aviv Sourasky Medical Center Institute of Gastroenterology and Liver Disease in 2005–2009.

Elinav earned a M.D. from the Hebrew University in Jerusalem in 1999. Following an internship and residency in internal medicine at the Hadassah-Hebrew University Medical Center in 2000–2004.

Eran Elinav (born 22 June 1969 in Jerusalem, Israel) is an Israeli immunologist and microbiota researcher at the Weizmann Institute of Science and the DKFZ.